DiaSorin S.p.A. (DIA) AI Stock Analysis

• Market Cap: €3.89B
• Dividend Yield: 1.8%
• Average Volume (3M): 221.33K
• Price to Earnings (P/E): 20.3
• Beta (1Y): 0.41
• Revenue Growth: 4.69%
• EPS Growth: 15.79%
• Country: IT
• Employees: 3,249
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.89
• Shares Outstanding: 55,948,257
• 10 Day Avg. Volume: 225,158
• 30 Day Avg. Volume: 221,334
• PEG Ratio: 1.70
• Price to Book (P/B): 3.09
• Price to Sales (P/S): 4.69
• P/FCF Ratio: 23.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €72.40
• Price Target Upside: 0.30% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: €76.00 ▲(5.29% Upside)

DiaSorin S.p.A. has a strong financial foundation, which is the most significant factor supporting its stock score. However, the technical analysis indicates bearish momentum, which negatively impacts the overall score. The valuation metrics are moderate, providing neither a strong upside nor downside. The absence of recent earnings call insights or notable corporate events leaves the financial performance as the primary driver of the stock's evaluation.

Positive Factors

Cash Flow Strength

Robust free cash flow growth and nearly 2x conversion of net income into cash provide durable internal funding for R&D, maintenance capex, dividends and targeted M&A. Strong cash conversion reduces refinancing risk and supports strategic investments over the next several quarters.

High Profitability Margins

Consistently high gross and operating margins indicate structural pricing power and operational efficiency in diagnostics. These margins create a durable buffer against volume fluctuations and pricing pressure, enabling sustained reinvestment and shareholder returns over the medium term.

Recurring Consumables Business Model

A consumables-based model tied to installed analyzers yields predictable, recurring revenue and higher lifetime customer value. Service contracts and reagent replenishment create switching costs and revenue visibility, supporting stable cash flows and planning stability over multiple quarters.

Negative Factors

Slow Revenue Growth

Modest organic revenue growth after prior decline suggests limited near-term top-line momentum and possible market saturation in core segments. Without faster new-product adoption or geographic expansion, revenue may constrain EPS and reinvestment capacity over the medium term.

Concentration on Consumables

Heavy dependence on consumables concentrates exposure to pricing pressure, competitive reagent offerings, or technological substitution. If reagents commoditize or core assays lose exclusivity, margin and growth could be structurally impaired absent diversification or new platform wins.

Limited Recent Guidance/Catalysts

The absence of recent earnings call insights or notable corporate events reduces forward-looking transparency for investors and limits visible catalysts. Over a multi-quarter horizon, this can hinder market confidence in strategic execution and slow external validation of growth initiatives.

DiaSorin S.p.A. Business Overview & Revenue Model

Company Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

How the Company Makes Money

DiaSorin generates revenue primarily through the sale of its diagnostic equipment and reagents to hospitals, laboratories, and healthcare facilities worldwide. The company's revenue model is heavily reliant on the recurring sales of consumables, specifically diagnostic kits and reagents that are used in conjunction with their proprietary analyzers. Key revenue streams include the installation and maintenance of diagnostic systems, as well as ongoing service contracts. Additionally, DiaSorin forms strategic partnerships with other pharmaceutical companies and research institutions to develop new diagnostic tests, which can further enhance its product offerings and market reach. The company's focus on innovation and expanding its product portfolio, especially in emerging markets, significantly contributes to its earnings.

DiaSorin S.p.A. Financial Statement Overview

Summary

DiaSorin S.p.A. is financially sound with strong profitability, effective cash flow generation, and a stable balance sheet. The company has demonstrated resilience in revenue growth and maintains a strategic balance between debt and equity, positioning it well for future growth and stability in the medical diagnostics industry.

Income Statement

DiaSorin S.p.A. exhibits strong profitability with a consistent gross profit margin of approximately 66% and a stable net profit margin around 16%. Revenue growth has shown resilience, recovering from a decline in 2022 to a growth of 3.2% in 2024. EBIT and EBITDA margins also reflect robust operational efficiency, with EBIT at 23% and EBITDA at 31% in 2024.

Balance Sheet

The company's balance sheet shows solid equity with a debt-to-equity ratio of 0.53, indicating prudent leverage. Return on equity has improved to 10.4% in 2024, showcasing effective shareholder value creation. The equity ratio remains healthy at 59.5%, reflecting financial stability and reduced risk exposure.

Cash Flow

DiaSorin S.p.A. demonstrates strong cash flow management, with a free cash flow growth of 34.9% in 2024. The operating cash flow to net income ratio is robust at 1.92, and the free cash flow to net income ratio stands at 1.92, indicating efficient conversion of profits into cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.22B	1.19B	1.15B	1.36B	1.24B	881.30M
Gross Profit	797.91M	781.00M	741.19M	900.61M	824.77M	602.90M
EBITDA	351.71M	399.04M	333.40M	479.71M	504.56M	383.62M
Net Income	191.50M	188.10M	159.85M	240.91M	310.97M	247.87M
Balance Sheet
Total Assets	2.87B	3.30B	3.21B	3.41B	3.23B	1.25B
Cash, Cash Equivalents and Short-Term Investments	182.96M	378.92M	403.39M	413.22M	403.02M	339.88M
Total Debt	769.18M	1.01B	1.19B	1.35B	1.40B	34.66M
Total Liabilities	1.34B	1.51B	1.67B	1.89B	1.86B	290.13M
Stockholders Equity	1.53B	1.80B	1.54B	1.52B	1.37B	954.68M
Cash Flow
Free Cash Flow	323.30M	239.07M	266.20M	275.65M	283.29M	229.74M
Operating Cash Flow	348.96M	358.78M	311.66M	389.34M	400.66M	304.56M
Investing Cash Flow	-66.76M	-49.81M	-29.10M	-231.95M	-1.61B	-73.02M
Financing Cash Flow	-258.59M	-259.13M	-235.96M	-333.04M	1.26B	-40.89M

DiaSorin S.p.A. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 72.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:DIA, the sentiment is Neutral. The current price of 72.18 is below the 20-day moving average (MA) of 73.14, above the 50-day MA of 66.71, and below the 200-day MA of 80.84, indicating a neutral trend. The MACD of 1.27 indicates Positive momentum. The RSI at 54.76 is Neutral, neither overbought nor oversold. The STOCH value of 30.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IT:DIA.

DiaSorin S.p.A. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHN	74 Outperform	€610.87M	34.71	―	1.86%	12.82%	7.37%
DIA	64 Neutral	€3.89B	20.32	12.16%	1.80%	4.69%	15.79%
GPI	63 Neutral	€518.47M	23.79	―	5.24%	11.25%	-76.44%
REC	60 Neutral	€9.56B	23.60	21.26%	2.67%	12.58%	-4.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%